Pfizer Inc. $PFE Stock Holdings Lowered by Apexium Financial LP

Apexium Financial LP reduced its holdings in Pfizer Inc. (NYSE:PFE) by 16.7% during the second quarter, Holdings Channel reports. The firm owned 12,158 shares of the biopharmaceutical company’s stock after selling 2,445 shares during the period. Apexium Financial LP’s holdings in Pfizer were worth $295,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also made changes to their positions in PFE. Brighton Jones LLC raised its holdings in shares of Pfizer by 1,282.4% in the 4th quarter. Brighton Jones LLC now owns 666,318 shares of the biopharmaceutical company’s stock worth $17,677,000 after purchasing an additional 618,117 shares in the last quarter. Revolve Wealth Partners LLC raised its holdings in shares of Pfizer by 12.5% during the fourth quarter. Revolve Wealth Partners LLC now owns 18,766 shares of the biopharmaceutical company’s stock valued at $498,000 after acquiring an additional 2,087 shares during the period. Vest Financial LLC raised its holdings in shares of Pfizer by 73.5% during the first quarter. Vest Financial LLC now owns 47,252 shares of the biopharmaceutical company’s stock valued at $1,197,000 after acquiring an additional 20,018 shares during the period. Signal Advisors Wealth LLC raised its holdings in shares of Pfizer by 16.6% during the first quarter. Signal Advisors Wealth LLC now owns 8,826 shares of the biopharmaceutical company’s stock valued at $224,000 after acquiring an additional 1,258 shares during the period. Finally, Insight Advisors LLC PA acquired a new stake in shares of Pfizer during the first quarter valued at approximately $215,000. 68.36% of the stock is currently owned by institutional investors.

Pfizer Trading Up 1.1%

Shares of NYSE:PFE opened at $27.37 on Friday. The firm has a fifty day moving average of $24.67 and a two-hundred day moving average of $24.14. The firm has a market capitalization of $155.59 billion, a P/E ratio of 14.56, a price-to-earnings-growth ratio of 0.88 and a beta of 0.55. Pfizer Inc. has a 12-month low of $20.92 and a 12-month high of $30.43. The company has a quick ratio of 0.85, a current ratio of 1.16 and a debt-to-equity ratio of 0.65.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.58 by $0.20. The company had revenue of $14.65 billion during the quarter, compared to analyst estimates of $13.43 billion. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The company’s revenue for the quarter was up 10.3% on a year-over-year basis. During the same quarter last year, the business posted $0.60 EPS. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. On average, equities analysts expect that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Analyst Ratings Changes

A number of research firms have recently issued reports on PFE. UBS Group restated a “neutral” rating and set a $28.00 price target on shares of Pfizer in a report on Wednesday. Citigroup boosted their price target on shares of Pfizer from $25.00 to $26.00 and gave the company a “neutral” rating in a report on Wednesday, August 6th. Morgan Stanley boosted their price target on shares of Pfizer from $32.00 to $33.00 and gave the company an “equal weight” rating in a report on Wednesday, August 6th. Bank of America boosted their price target on shares of Pfizer from $28.00 to $30.00 and gave the company a “neutral” rating in a report on Friday. Finally, Weiss Ratings restated a “hold (c-)” rating on shares of Pfizer in a report on Saturday, September 27th. Two investment analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, twelve have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $28.41.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.